
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


MacroGenics Inc (MGNX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: MGNX (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 98.88% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 163.18M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 662040 | Beta 2.08 | 52 Weeks Range 2.37 - 21.88 | Updated Date 02/10/2025 |
52 Weeks Range 2.37 - 21.88 | Updated Date 02/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -69.07% | Operating Margin (TTM) 48.95% |
Management Effectiveness
Return on Assets (TTM) -22.15% | Return on Equity (TTM) -62.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3078036 | Price to Sales(TTM) 1.15 |
Enterprise Value -3078036 | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 62763400 | Shares Floating 51742814 |
Shares Outstanding 62763400 | Shares Floating 51742814 | ||
Percent Insiders 2.65 | Percent Institutions 93.19 |
AI Summary
MacroGenics Inc. Overview:
Company Profile:
History and Background:
MacroGenics Inc. (NASDAQ: MGEN) was founded in 2000 and is headquartered in Rockville, Maryland. The company focuses on discovering and developing innovative antibody-based therapies for the treatment of cancer, autoimmune diseases, and infectious diseases. MacroGenics utilizes its proprietary DART® (Dual Affinity Re-Targeting) platform technology to create bispecific and trispecific antibody-based therapeutics.
Core Business Areas:
- Oncology: Development of antibody-based therapies for the treatment of various cancers, such as solid tumors, hematologic malignancies, and immunotherapy.
- Infectious Diseases: Focus on developing antibody-based therapies for infectious diseases like HIV and COVID-19.
- Autoimmune Diseases: Targeting autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease.
Leadership and Corporate Structure:
- President and Chief Executive Officer: Scott Koenig, M.D., Ph.D.
- Executive Vice President and Chief Financial Officer: Patricia S. Conti
- Senior Vice President and Chief Scientific Officer: Daniel A. Vallera, Ph.D.
- Board of Directors: Comprises experienced leaders in the pharmaceutical and biotechnology industry.
Top Products and Market Share:
- Margetuximab (Margenza®): A CD38-directed monoclonal antibody for the treatment of multiple myeloma, approved in the US and Europe. Holds a market share of approximately 10% in the US market for CD38-directed therapies.
- Tecovirimat (TPOXX®): An antiviral drug for the treatment of smallpox, approved by the FDA.
- MGD013: An investigational bispecific antibody targeting both B7-H3 and PD-L1, currently in Phase 2 clinical trials for various cancers.
Total Addressable Market:
The global market for oncology drugs is expected to reach $248.2 billion by 2025. The autoimmune disease market is projected to reach $235.5 billion by 2027.
Financial Performance:
Recent Financials:
- Revenue: $69.3 million (2022)
- Net Income: ($100.3 million) (2022)
- Profit Margin: -144.6% (2022)
- Earnings per Share (EPS): ($2.15) (2022)
Year-over-Year Performance:
- Revenue has grown by 19% from 2021.
- Net loss has increased from 2021.
- Cash flow is negative, reflecting investments in R&D and clinical trials.
Dividends and Shareholder Returns:
- Dividend History: MacroGenics does not currently pay dividends.
- Shareholder Returns: Share price has declined significantly over the past year.
Growth Trajectory:
Historical Growth: Revenue has grown steadily over the past few years, driven by the launch of Margenza and the advancement of its pipeline.
Future Growth Projections: MacroGenics expects to achieve profitability in 2025, driven by Margenza sales and potential approval of other pipeline candidates.
Market Dynamics:
The pharmaceutical and biotechnology industry is highly competitive and constantly evolving. MacroGenics faces challenges from established players and innovative startups in the field of antibody-based therapies.
Key Competitors:
- Amgen (AMGN)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
- Regeneron (REGN)
- Seagen (SGEN)
- Immunomedics (IMMU)
- ImmunoGen (IMGN)
- Argenx (ARGX)
Potential Challenges and Opportunities:
- Challenges: Competition, successful development and commercialization of pipeline candidates, regulatory hurdles, and intellectual property issues.
- Opportunities: Growing demand for novel cancer therapies, expansion into new markets, potential partnerships with larger pharmaceutical companies.
Recent Acquisitions (last 3 years):
- 2021: Acquired exclusive worldwide rights for the DART protein MGD023 from Xencor, Inc.
- 2020: Acquired exclusive worldwide rights for the DART protein MGD013 from Xencor, Inc.
- 2020: Acquired exclusive worldwide rights for the DART protein MGD019 from Xencor, Inc.
AI-Based Fundamental Rating:
MacroGenics receives a 5 out of 10 rating. While the company has promising pipeline candidates and a unique technology platform, it faces profitability challenges, competition, and market volatility.
Disclaimer:
This analysis is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | President, CEO & Director Dr. Scott Koenig M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 339 | Website https://www.macrogenics.com |
Full time employees 339 | Website https://www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.